NO20063960L - Fremgangsmate for a oke biotilgjenlighenten av ospemifen - Google Patents

Fremgangsmate for a oke biotilgjenlighenten av ospemifen

Info

Publication number
NO20063960L
NO20063960L NO20063960A NO20063960A NO20063960L NO 20063960 L NO20063960 L NO 20063960L NO 20063960 A NO20063960 A NO 20063960A NO 20063960 A NO20063960 A NO 20063960A NO 20063960 L NO20063960 L NO 20063960L
Authority
NO
Norway
Prior art keywords
ospemifene
bioavailability
increasing
prevention
treatment
Prior art date
Application number
NO20063960A
Other languages
English (en)
Other versions
NO337656B1 (no
Inventor
Markku Anttila
Original Assignee
Hormos Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34837941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20063960(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hormos Medical Corp filed Critical Hormos Medical Corp
Publication of NO20063960L publication Critical patent/NO20063960L/no
Publication of NO337656B1 publication Critical patent/NO337656B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Det beskrives en fremgangsmåte for å øke biotilgjengeligheten av ospemifen eller en geometrisk isomer, en stereoisomer, et farmasøytisk aktivt salt, en ester eller en metabolitt derav, hvor nevnte forbindelse administreres vedkommende peroralt i forbindelse med næringsinntaket. Behandlingen eller forebyggelsen av osteoporose, hudatrofi, epitel- og mukosa-atrofi, så vel som behandling eller forebyggelse av urinale eller vaginale symptomer, beskrives også.
NO20063960A 2004-02-13 2006-09-05 Anvendelse av ospemifen for fremstilling av en farmasøytisk blanding for behandling eller forebygging av osteoporose, symptomer relatert til hudatrofi, eller symptomer relatert til epitel eller mukosal atrofi NO337656B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/777,211 US8236861B2 (en) 2004-02-13 2004-02-13 Method for enhancing the bioavailablity of ospemifene
PCT/FI2005/000018 WO2005077350A1 (en) 2004-02-13 2005-01-14 Method for enhancing the bioavailability of ospemifene

Publications (2)

Publication Number Publication Date
NO20063960L true NO20063960L (no) 2006-11-03
NO337656B1 NO337656B1 (no) 2016-05-23

Family

ID=34837941

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20063960A NO337656B1 (no) 2004-02-13 2006-09-05 Anvendelse av ospemifen for fremstilling av en farmasøytisk blanding for behandling eller forebygging av osteoporose, symptomer relatert til hudatrofi, eller symptomer relatert til epitel eller mukosal atrofi
NO20151603A NO339190B1 (no) 2004-02-13 2015-11-25 Anvendelse av en terapeutisk aktiv forbindelse for fremstilling av en farmasøytisk blanding for behandling eller forebygging av seksuell dysfunksjon

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20151603A NO339190B1 (no) 2004-02-13 2015-11-25 Anvendelse av en terapeutisk aktiv forbindelse for fremstilling av en farmasøytisk blanding for behandling eller forebygging av seksuell dysfunksjon

Country Status (21)

Country Link
US (5) US8236861B2 (no)
EP (1) EP1713458B1 (no)
JP (2) JP5577011B2 (no)
CN (1) CN1925847A (no)
AT (1) ATE387910T1 (no)
AU (1) AU2005211958B2 (no)
BR (1) BRPI0507661A (no)
CA (1) CA2556089C (no)
CY (2) CY1111014T1 (no)
DE (1) DE602005005165T2 (no)
DK (1) DK1713458T5 (no)
ES (1) ES2302177T3 (no)
HU (1) HUS1500030I1 (no)
LT (1) LTC1713458I2 (no)
LU (1) LU92736I2 (no)
MX (1) MXPA06009274A (no)
NO (2) NO337656B1 (no)
PL (1) PL1713458T3 (no)
PT (1) PT1713458E (no)
RU (1) RU2385716C2 (no)
WO (1) WO2005077350A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US8642079B2 (en) * 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US8758821B2 (en) * 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
EP1742618B1 (en) 2004-05-04 2012-08-22 Hormos Medical Ltd. Liquid oral formulations of ospemifene
AU2006339325A1 (en) * 2005-11-09 2007-09-07 Hormos Medical Ltd. Formulations of fispemifene
US8546451B2 (en) * 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8637706B2 (en) 2005-11-28 2014-01-28 Gtx, Inc. Nuclear receptor binding agents
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
EA201500845A1 (ru) * 2005-11-28 2016-04-29 Джи Ти Икс, ИНК. Агенты, связывающиеся с ядерными рецепторами
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
CN101636372B (zh) * 2007-02-14 2013-03-27 霍尔莫斯医疗有限公司 有治疗价值的三苯基丁烯衍生物的制备方法
WO2008099060A2 (en) * 2007-02-14 2008-08-21 Hormos Medical Ltd Methods for the preparation of fispemifene from ospemifene
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
WO2014060639A1 (en) 2012-10-19 2014-04-24 Fermion Oy A process for the preparation of ospemifene
CN103739456A (zh) * 2013-12-03 2014-04-23 镇江圣安医药有限公司 2-（对-（（z-4-氯-1,2-二苯基-1-丁烯基）苯氧基）乙醇的新型衍生物及其应用
GR1009542B (el) 2018-04-25 2019-06-07 Φαρματεν Α.Β.Ε.Ε. Καψουλα μαλακης γελης που περιλαμβανει εναν εκλεκτικο ρυθμιστη οιστρογονικων υποδοχεων
WO2019217924A1 (en) 2018-05-11 2019-11-14 Xenon Pharmaceuticals Inc. Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9207437D0 (en) 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
GB9418067D0 (en) * 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
GB9604577D0 (en) 1996-03-04 1996-05-01 Orion Yhtymae Oy Serum cholesterol lowering agent
ES2255294T3 (es) * 1998-08-07 2006-06-16 Chiron Corporation Derivados de isoxazol sustituidos como moduladores del receptor de estrogenos.
US6219674B1 (en) 1999-11-24 2001-04-17 Classen Immunotherapies, Inc. System for creating and managing proprietary product data
US6245819B1 (en) * 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
US6653639B1 (en) * 2000-10-17 2003-11-25 Nikon Corporation Chuck for mounting reticle to a reticle stage
CA2438816A1 (en) 2001-02-22 2002-09-06 Classen Immunotherapies, Inc. Improved algorithms and methods for products safety
FR2826811B1 (fr) 2001-06-27 2003-11-07 France Telecom Procede d'authentification cryptographique
CA2484542C (en) 2002-06-06 2010-11-02 Hormos Medical Corporation Method for the inhibition of atrophy or for treatment or prevention of atrophy-related symptoms in women
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US8642079B2 (en) 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US20050187302A1 (en) 2004-02-23 2005-08-25 Hormos Medical Corporation Method for treatment or prevention of osteoporosis in individuals with high bone turnover
US8758821B2 (en) 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
US20060293294A1 (en) 2004-09-03 2006-12-28 Hormos Medical Corporation Method for treatment or prevention of androgen deficiency

Also Published As

Publication number Publication date
EP1713458A1 (en) 2006-10-25
DE602005005165T2 (de) 2009-04-30
CA2556089A1 (en) 2005-08-25
MXPA06009274A (es) 2007-04-16
US20050182143A1 (en) 2005-08-18
AU2005211958B2 (en) 2010-11-25
US8236861B2 (en) 2012-08-07
RU2385716C2 (ru) 2010-04-10
US20160101065A1 (en) 2016-04-14
US20120270952A1 (en) 2012-10-25
JP6023119B2 (ja) 2016-11-09
NO337656B1 (no) 2016-05-23
NO20151603L (no) 2006-11-03
WO2005077350A1 (en) 2005-08-25
US9241915B2 (en) 2016-01-26
RU2006132719A (ru) 2008-03-20
US20130324614A1 (en) 2013-12-05
LTPA2015023I1 (lt) 2015-08-25
DK1713458T3 (da) 2008-07-07
CY2015027I2 (el) 2016-04-13
CY1111014T1 (el) 2015-06-11
EP1713458B1 (en) 2008-03-05
BRPI0507661A (pt) 2007-07-17
DK1713458T5 (da) 2008-09-29
US20140303259A1 (en) 2014-10-09
CY2015027I1 (el) 2016-04-13
ATE387910T1 (de) 2008-03-15
PT1713458E (pt) 2008-05-07
ES2302177T3 (es) 2008-07-01
US8470890B2 (en) 2013-06-25
CA2556089C (en) 2013-04-02
DE602005005165D1 (de) 2008-04-17
JP2007522190A (ja) 2007-08-09
JP5577011B2 (ja) 2014-08-20
LU92736I2 (fr) 2015-08-10
US9855224B2 (en) 2018-01-02
PL1713458T3 (pl) 2008-08-29
LTC1713458I2 (lt) 2017-06-26
US8772353B2 (en) 2014-07-08
AU2005211958A1 (en) 2005-08-25
CN1925847A (zh) 2007-03-07
JP2014141533A (ja) 2014-08-07
HUS1500030I1 (hu) 2015-08-28
NO339190B1 (no) 2016-11-14

Similar Documents

Publication Publication Date Title
NO20063960L (no) Fremgangsmate for a oke biotilgjenlighenten av ospemifen
EA200800147A1 (ru) Способ получения олмесартан медоксомила
WO2008040534A3 (en) Non-mucoadhesive film dosage forms
AU2009258040A8 (en) Compounds and method for reducing uric acid
MY160074A (en) Protopanaxadiol-type ginsenoside compositions and uses thereof
WO2007035515A3 (en) A method of intraepithelial and systemic exposure of therapeutic agents following vaginal and oral cavity administration
DK1427297T3 (da) Appetitnedsættende procyanidin-holdigt præparat til pattedyr
UA96304C2 (en) 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
SG141358A1 (en) Treatment of psychiatric patients with reduced heptaic function with paliperidone
WO2006039414A3 (en) Treatment method
EA200500764A1 (ru) Фармацевтические композиции и лекарственные формы для трансбуккальной и сублингвальной доставки тизанидина и способы введения тизанидина сублингвально или трансбуккально
WO2008061671A3 (en) Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
WO2006113571B1 (en) Substituted cyclopentanones for treating inflammatory bowel disease
TW200420304A (en) Orally administrable pharmaceutical compositions and methods for preventing food-drug interaction
WO2010041889A3 (en) Pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease
NO20044568L (no) Fremgangsmate for inhibering av atrofi eller for behandling eller forhindring av atrofi-relaterte symptomer i kvinner
JP2007506780A5 (no)
WO2007133476A3 (en) Competitive substrate inhibition to increase drug bioavailability
NO20081264L (no) Krystallinske former av {(1R),2S]-2-Aminopropionsyre 2-[4-(4-Fluor-2-Metyl-1H-Indol-5-Yloksy)-5-Metylpyrrolo[2,1-F][1,2,4]Triazin-6-Yloksy]-1-Metyletylester
WO2008009589A3 (en) Kit of parts comprising an acid labile and an acid resistant pharmaceutically active ingredient
ElMaraachli et al. An Unusual Cause Of Chronic Cough
RU2006135006A (ru) Способ лечения больных язвенной болезнью
RU2004125211A (ru) Способ профилактики заболеваний птиц
WO2008093767A1 (ja) ベンジルアミン誘導体またはその薬学的に許容される酸付加塩、およびその医薬用途
WO2008117790A1 (ja) フコイダンを有効成分とする酸性尿改善飲食物および経口投与用医薬組成物